Modeling heart failure, however, can be challenging because heart failure results from a myriad of causes with distinct clinical features that need to be incorporated into animal models. 2 Heart failure is also characterized by gradual deterioration of left ventricular (LV) function over a typical span of several years, which has been difficult to incorporate into existing animal models.
Ischemic cardiomyopathy models were first developed in rats. Scientists created surgical models of myocardial infarction by either ligating or occluding the left anterior descending artery (LAD), causing left ventricular dysfunction. Rat models are generally preferable to mice because their larger size facilitates the performance of multimodality imaging, invasive hemodynamics, and histological analysis. 3 The major advantage of mice, however, is the availability of transgenic and knockout strains and lower housing costs. With the advent of micro-imaging technology at specialized centers, 4 ,5 the use of murine heart failure models has become more common albeit with greater expense for imaging. Importantly, the benefits of many of the heart failure therapies to date have first been observed in small animals. Using a rat model of myocardial infarction, for example, Pfeffer et al reported that ACE inhibitors reduced left ventricular (LV) dilatation, increased ejection fraction, and improved survival in rats with moderate to large infarcts. 6 More recently, the role of calmodulin kinase II (CaMKII) in the causation and progression of cardiac hypertrophy was elucidated in mice. 7, 8 Subsequent studies in large animals and humans have shown that an increased expression of CAMKII in the myocardium is associated with the development of heart failure after myocardial infarction. 9, 10 Demonstration of efficacy and safety in small animal models alone, however, is insufficient for clinical translation and regulatory approval because significant differences exist in the physiological characteristics of small animals vs those in humans. Murine hearts, for example, beat over 600 times per minute (*8-10 times faster than human heart), which suggests that different mechanisms regulate calcium influxes. 3 These fundamental differences in physiology can result in mice having a completely opposite response to genetic mutations than humans, as demonstrated in a study by Haghighi et al which showed that while the ablation of gene encoding phospholamban improved murine heart function, hereditary mutation of this protein in humans leads to the development of lethal cardiomyopathy. 11 The concentration of sarcomeric proteins is also significantly different in murine and human hearts. While alpha myosin heavy chain comprises more than 95% of the total myofibrillar protein in murine left ventricles, beta myosin heavy chain protein is the major isoform in human hearts, comprising 90%. 11 Because myofibril proteins differ in their ATP utilization and contractile force generation, their response to myocardial injury and genetic mutation may not be equal. 12 Thus, while rodents provide a highthroughput, relatively inexpensive in vivo biological system to study human disease, these models can fall short of recapitulating the pathophysiology of heart failure in humans, and preliminary findings need to be confirmed using large animal models.
Because large animals are physiologically closer to humans, large animal models can potentially bridge the gap between experimental discoveries and clinical applications. Like humans, the heart rates of larger mammals are slower than those of rodents. The left ventricles of larger animals also have similar concentrations of myofibrils. 13 The most common animals used for large animal models are rabbits, dogs, sheep, and pigs. The most frequent procedures used to induce left ventricular dysfunction include coronary ligation and microembolization, 14, 15 which create permanent macrovascular and microvascular injury, respectively, and coronary balloon catheter occlusion for various durations, which results in ischemia reperfusion injury. 16, 17 The advantages and disadvantages of various large animal models in ischemic cardiomyopathy are detailed in Table 1 .
In this edition of the journal, Tarkia et al re-introduce a model of ischemia reperfusion injury that uses a combination of ligation of the distal portion of the LAD followed by proximal occlusion, a model that was previously presented by Teramoto et al 18 The reported advantage of this model is the creation of larger myocardial infarctions with acceptable survival rates due to ''preconditioning'' effect of distal LAD ligation. Compared to existing models (Table 2) , the ''new'' model successfully creates much larger infarct sizes that result in a larger decrease in ejection fraction. 18 Not surprisingly, the larger infarct sizes, however, resulted in a much higher mortality rate than observed in other models. [14] [15] [16] [17] 19 The question remains whether the benefit of larger infarct size outweighs the significant costs of over 50% mortality among instrumented animals.
When considering this model as opposed to others, investigators should balance the cost of lower incidence of CHF among instrumented animals against the cost of high mortality that includes costs for housing, noninvasive and invasive procedural, and personnel for animals that ultimately do not undergo randomization. On the other hand, investment in models that closely mimic disease in humans has greater payoffs downstream. A systematic review of animal studies cited in seven leading journals found that only a third of the studies were translated into randomized clinical trials and only a tenth of those were subsequently approved for human patients. 20 This means that the majority of interventions that showed efficacy in animal models failed to show benefit in humans. Notable examples of these interventions include therapies that were developed to reduce reperfusion injury in myocardial infarction and to protect the brain from additional injury after stroke. [21] [22] [23] [24] More recently, disappointing results from randomized controlled clinical trials using bone marrowderived stem cells for cardiac regeneration provide further support that improved efficacy observed in preclinical models cannot always be replicated in humans. 25 Perhaps the failure of clinical trials to show benefit noted in animal models speaks more to the need for a more sensitive measure than ejection fraction to evaluate therapeutic efficacy. Because clinical trials are conducted in less controlled settings than animal studies, small changes in ejection fraction may be ''washed out'' by individual differences in response to treatment or by other experimental variability. In addition to incorporating structural and functional measures to assess heart failure progression, Tarkia et al have introduced the potential of measuring myocardial efficiency to differentiate diseased from normal myocardium. Myocardial efficiency is defined as the ratio of useful work to oxygen consumption. 26 Efficiency is reduced in heart failure because energy expenditure increases more than myocardial work. Previous studies have shown that poor myocardial efficiency is associated with death, 27 and efficiency improves with administration of heart failure therapy, 28, 29 suggesting that myocardial efficiency could be a valuable surrogate marker for therapeutic monitoring.
Noninvasive measures of oxygen consumption and myocardial work are promising methods to estimate myocardial efficiency. 26 To estimate oxygen consumption, Tarkia et al incorporated positron emission tomography (PET) using 11 C-acetate, which is considered the most accurate noninvasive measure of oxygen consumption. 30 PET imaging of 11 C-acetate operates on the following principle: After its introduction into the blood stream, acetate is taken up by the myocardium, rapidly converted to acetyl-coenzyme A, oxidized in the tricarobxylic acid (TCA) cycle, and released as 11 Ccarbon dioxide. Because the TCA cycle is tightly coupled with oxidative phosphorylation, myocardial clearance of 11 C-acetate (as carbon dioxide) can estimate oxygen consumption. However, using a single compartment model to measure myocardial kinetics of 11 C-acetate turnover, Tarki et al found only a small change in oxygen consumption between control and infarcted animals, which may reflect the dependence of this measure on correct estimates of 11 C-acetate blood activity and high image quality. 26 To estimate myocardial work, an assessment of LV structure and function is also required. Tarkia et al used echocardiography and computed tomographic angiography to assess stroke volume and LV mass, respectively. Although both imaging modalities provide adequate estimation of these parameters, the use of a multimodality approach to measure myocardial efficiency may confound results because hemodynamics may vary among the three imaging approaches. Cardiac MRI is a promising approach that allows investigators to measure both workload and oxygen consumption sequentially in the same imaging session. Cardiac MRI is already considered the gold standard for the noninvasive evaluation of stroke volume and LV mass. Recently, investigators have successfully used T2-based cardiac MR imaging sequences to measure oxygen consumption in large animals and normal volunteers, 31, 32 capitalizing on the relationship between the T2 blood relaxation rate and the presence of paramagnetic deoxyhemoglobin in red blood cells. Importantly, cardiac MRI can measure ejection fraction, chamber sizes, regional wall motion abnormalities, myocardial perfusion and viability, all of which are important measures of therapeutic efficacy in large animal models. Even with these comprehensive measures to evaluate therapeutic efficacy, however, large animal models may not completely close the translational gap because animals lack identical genotypic and phenotypic characteristics as humans, and thus may not respond exactly the same to physical insults, disease processes, or therapy.
Human-induced pluripotent stem cell (iPSC) technology may facilitate the clinical translation of novel therapies for heart failure ( Figure 1 ). Discovered in 2007 by Shinya Yamanka and James Thompson, 33, 34 human iPSCs are isolated from adult somatic cells including skin, blood, and other tissues, and then ''reprogrammed'' to their pluripotent state. Human iPSCs can be differentiated to various cell types such as cardiomyocytes and endothelial cells that possess similar morphological, biochemical, electrophysiological, genomic, and mechanical properties as those of primary human cells. 35 Human iPSC derivatives have been shown to accurately model certain disease processes at the single cell level, making them ideal for evaluating potential therapies prior to Phase I clinical trials. The most extensively studied cardiac diseases modeled by iPSC technology include inherited disorders such as arrhythmic disorders caused by mutations in ion channels (ion chanelopathies) and cardiomyopathies 36 (e.g., dilated cardiomyopathy, 37 hypertrophic cardiomyopathy, 38 and arrhythmogenic right ventricular dysplasia/ cardiomyopathy 39 ). Using human iPSC technology, investigators can conduct a ''clinical trial in a dish'' before investing in expensive studies in humans, thus eliminating therapies that may be effective in animals but not in humans.
Bringing novel therapies to the clinic for the management of heart failure is an arduous and expensive process with more failures than successes. Improving the efficiency of this process requires the creation of models that most closely replicate human conditions, as well as the incorporation of efficacy measures that reflect meaningful endpoints. It will be important for investigators and regulatory agencies to embrace technological advances such as those discussed here in order to ensure that novel therapies can be delivered expeditiously to patients suffering from heart failure.
